Large granular lymphocytic leukemia
Drug research and approvals for large granular lymphocytic leukemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 15 studies of large granular lymphocytic leukemia are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 15
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative DiseasesNCT07727083 · Not reported · Rong Tao · starts Aug 11, 2026
- A Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte LeukemiaNCT07692529 · Phase 1 · Institute of Hematology & Blood Diseases Hospital, China · starts Oct 1, 2026
- National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic LeukemiaNCT07019766 · Not reported · Institute of Hematology & Blood Diseases Hospital, China · starts Jan 1, 2000
- JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell LymphomasNCT06716658 · Phase 2 · Institute of Hematology & Blood Diseases Hospital, China · starts Dec 25, 2024
- PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell LymphomasNCT06530550 · Phase 2 · Institute of Hematology & Blood Diseases Hospital, China · starts Aug 10, 2024
- Thalidomide for the Symptomatic Large Granular Lymphocytic LeukemiaNCT06530576 · Phase 2 · Institute of Hematology & Blood Diseases Hospital, China · starts Aug 10, 2024
- A Registry for People With T-cell LymphomaNCT05978141 · Not reported · Memorial Sloan Kettering Cancer Center · starts Jul 27, 2023
- Safety Evaluation Study for Patients With Aggressive NK-cell LeukemiaNCT05863234 · Phase 1 / Phase 2 · Hiroshima University Hospital · starts Sep 21, 2023
- Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic LeukemiaNCT05592015 · Phase 2 · Jonathan Brammer · starts May 3, 2023
Phase 2 7
- AlemtuzumabCAMPATH-1 antigen inhibitor
- CyclosporineCyclophilin A modulator
- MethotrexateDihydrofolate reductase inhibitor
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- TacrolimusFK506-binding protein 1A inhibitor
- RuxolitinibTyrosine-protein kinase JAK1 inhibitor
- TipifarnibProtein farnesyltransferase inhibitor
Phase 1 or earlier 4
- DasatinibTyrosine-protein kinase ABL inhibitor
- AzacitidineDNA (cytosine-5)-methyltransferase 3A inhibitor
- HUMIK-beta-1Interleukin-2 receptor beta chain inhibitor
- Ulviprubart
How its trials ended
59 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 22 whose ending is known, 32% met their primary endpoint, 5% missed it and 64% stopped early.
- Completed, result not reported2339%
- Ongoing1322%
- Met its primary endpoint712%
- Stopped: other or unclear712%
- Stopped: enrollment or feasibility58%
- Missed its primary endpoint12%
- Stopped: sponsor or business decision12%
- Stopped: funding12%
- Status unknown12%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA